- PLN138.21m
- PLN134.59m
- PLN6.02m
Brief: Molecure Says Its In-Consortium Project Selected For Funding By Medical Research Agency
Brief: Molecure To Sell 4.12 Mln Series K Shares and 2.0 Mln Existing Shares At 5 Zlotys/Shr
Brief: Molecure Starts ABB For Up to 4.12 Mln New Series K Shares And Up To 2.0 Mln Existing Shares
Brief: Molecure Signs Conditional Investment Agreement With MS Galleon And Szumowski Investments
Brief: Molecure To Increase Share Capital Via Issue Of Up To 4,120,631 New Series K Shares
Brief: Molecure FY Operating Revenue PLN 6.5 Mln
Brief: Molecure Decides To Close RNA Project
Brief: Molecure Signs Subsidy Agreement With Poland's National Centre For R&D
Brief: Molecure Q3 Net Loss At 5.3 Million Zlotys
Brief: Molecure H1 Net Loss At 8.7 Mln Zlotys
Brief: Molecure Announces Positive Evaluation Of Project For Subsidy By Poland's National Centre For R&D
Brief: Molecure Adopts Regulations For Group Layoffs
Brief: Molecure Commences Group Layoff Procedure
Brief: Molecure FY Net Loss At 31.3 Mln Zlotys
Brief: Molecure Says Agnieszka Rajczuk-Szczepanska And Slawomir Broniarek Resign
Brief: Molecure Starts Bookbuilding Process For 3.4 Mln I Series Shares
Brief: Molecure To Save 13 Mln Zloty By End-2025 Due To Project Pipeline Changes
Brief: Molecure (Wse Moc) And Nasdaq-Listed Biotechnology Company Ocean Biomedical (Nasdaq Ocea) Sign An Exclusive Licensing Agreement For The Development And Commercialization Of Selective Ykl-40 Inhibitors
Brief: Molecure Signs Exclusive Licensing Deal With Ocean Biomedical